Please login to the form below

Not currently logged in
Email:
Password:

Martin Shkreli

This page shows the latest Martin Shkreli news and features for those working in and with pharma, biotech and healthcare.

Profit: the ugly, dirty truth?

Profit: the ugly, dirty truth?

That's the ugly, dirty truth.”. One of the most infamous quotes (of many) from a certain Martin Shkreli, the so-called ‘Pharma Bro’, currently serving seven years for fraud in

Latest news

  • Theranos and its CEO settle 'massive fraud' charges Theranos and its CEO settle 'massive fraud' charges

    A separate case will proceed again Balwani. Holmes will, however, avoid jail time, unlike former Turing CEO Martin Shkreli, who was arrested in 2015 by the FBI on securities fraud charges

  • Connecting the dots Connecting the dots

    In a world like this, how many Marathons, Valeants and Martin Shkreli’s do you think there would be?

  • Making a list and checking it twice… Making a list and checking it twice…

    Let's start with an obvious one: prices and price increases. The hangover effect of Martin Shkreli and Valeant Pharmaceuticals in 2015 continued to haunt the industry along with new dramas

  • EpiDemic EpiDemic

    And the next egregious drug-pricing headline is yet to come. But like Valeant and Martin Shkreli before it, the EpiPen narrative teaches us some important lessons.

  • Retrophin rockets away as rare disease trial hits targets Retrophin rockets away as rare disease trial hits targets

    Last year, Retrophin was indirectly caught up in the scandal surrounding its founder Martin Shkreli - who was eventually fired by the board and faced allegations of using company stock to pay ... Sparsentan was brought into Retrophin's pipeline by

More from news
Approximately 5 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    treat toxoplasmosis, being given a 5, 000% price increase ($13.50 per pill to $750), to “ fund future research into the disease” and the subsequent backlash against its CEO Martin Shkreli ... in net cash to fund its near-term development needs and

  • Pharma deals during February 2014 Pharma deals during February 2014

    According to Martin Shkreli, founder and CEO: “ We also intend to move quickly to pursue FDA approval of Chenodal for CTX.".

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics